痰热清注射液治疗急性肺炎(痰热壅肺证)  

Tanreqing Injection in Treatment of Acute Pneumonia(Ayndrome of Phlegm-Heat Obstructing Lung)

作　　者：刘维军[1] 孙丽[1] 李笃印 

机构地区：[1]天津市宁河县医院药剂科,天津301500

出　　处：《中国实验方剂学杂志》2014年第10期220-222,共3页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家科技部"973"计划项目(2010258);天津市医药卫生科技攻关项目(11KG141)

摘　　要：目的:探讨痰热清注射液治疗急性肺炎(痰热壅肺证)的临床疗效。方法:将急性肺炎(痰热壅肺证)患者随机分为研究组和对照组,两组患者均给予纠正电解质紊乱、吸痰、解痉平喘、白三烯稳定剂、控制血糖、控制血压、纠正心衰、调脂及其他对症等常规治疗,对照组患者在常规治疗的基础上给予双黄连注射液20 mL加入5%葡萄糖注射液500 mL静滴,每日1次。治疗组在常规治疗的基础上给予痰热清注射液20 mL加入5%葡萄糖注射液500 mL静滴,每日1次;两组患者均以2周为1个疗程。比较两组患者的临床疗效及不良反应发生情况。结果:本研究两组患者在经过2周积极的治疗后,研究组患者的总有效率(90.63%)明显高于对照组(68.75%)(P<0.05)。研究组患者的发热、咳嗽消除时间[(41.35±21.32)h,(70.71±33.65)h]较对照组[(50.85±28.33)h,(80.36±41.03)h]明显缩短(P<0.05)。两组患者在治疗过程中均未出现听力减退、急性肝肾损害;研究组患者中有1例出现治疗后心电图QT间期延长,而对照组患者中未出现任何不良反应,经统计学分析发现,研究组的不良反应发生率与对照组比较无明显差异。结论:痰热清注射液治疗急性肺炎(痰热壅肺证)的临床疗效确切,不良反应少,值得临床推广使用。Objective： To investigate the effect of Tanreqing injection in treatment of acute pneumonia （syndrome of phlegm-heat obstructing lung）. Method： The acute pneumonia February were （syndrome of phlegm-heat obstructing lung） patients were randomly divided into study group and control group. Patients of two groups were given correct electrolyte disorders, sputum suction, antispasmodic asthma, leukotriene stabilizer, controling blood glucose, blood pressure, heart failure, lipid and other symptomatic treatment. Patients of the control group were given Shuanghuanglian injection 20 mL in 5% glucose injection 500 mL based on above conventional treatment, intravenous drip, one time per day. The treatment group was given Tanreqing injection 20 mL in 5% glucose injection 500 mL by intravenous drip based on above conventional treatment, one time per day. 2 weeks were as a course of treatment. Clinical efficacy and adverse reactions were compared between two groups. Result： 2 weeks after treatment, patients in the study group the total efficiency （90.63%） significantly higher than that in control group （68.75%）, and the difference was statistically significant （P〈0.05）. Heating time and eliminate time in the study group were significantly shorter than that in the control group [（41.35±21.32）h, （70.71±33.65）h] were significantly shorter than that in the control group[（50.85±28.33）h,（80.3641.03）h], and the difference was statistically significant （P〈0.05）. Patients in two groups during treatment had no hearing loss, acute kidney damage;there were 1 cases of treatment of electrocardiograph（ECG） after prolonged QT interval in patients of the study group, while patients in the control group without any adverse reactions, by statistical analysis of the incidence of adverse reaction in group with no significant difference compared to control group. Conclusion： Tanreqing injection in the treatment of acute pneumonia （syndrome of phlegm-heat obstructing lung） has clinical c

关 键 词：痰热清注射液 急性肺炎 痰热壅肺证 

分 类 号：R287[医药卫生—中药学]